Horizon Discovery Group plc Notice of Full Year Results (3682T)

TIDMHZD

RNS Number : 3682T

Horizon Discovery Group plc

20 March 2019

Horizon Discovery Group plc

Notice of Full Year Results

Cambridge, UK, 20 March 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon"), a global leader in the application of gene editing and gene modulation technologies, today announces that its full year results for the year ended 31 December 2018 will be announced on Monday 29 April 2019.

Terry Pizzie, Chief Executive Officer, and Jayesh Pankhania, Chief Financial Officer, will host a presentation for analysts and live conference call at 12.00pm BST / 7:00am EST on the morning of results at the offices of Numis, 10 Paternoster Square, London, EC4M 7LT.

A live webcast of the meeting, with the presentation slides, will be available on Horizon's Investor Relations website.

ENDS

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

Tel: [phone]

Numis Securities Limited (Broker and NOMAD)

Freddie Barnfield / James Black / Duncan Monteith

Tel: [phone]

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: [phone]

Email: [e-mail]

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR, Transposon and base editing) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker HZD

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NORDGGDXLBBBGCC

(END) Dow Jones Newswires

March 20, 2019 03:02 ET (07:02 GMT)